After experimental drug treatment, fatal brain tumors in humans disappear
newYou can listen to Fox’s news articles!
The most deadly shape man Brain tumor There are no signs of illness after taking the experimental medication.
Ben Trotman was 40 years old when he was diagnosed with glioblastoma, the most aggressive cancerous brain tumor in 2022. Patients typically live on an average of 15 months after diagnosis, with a 5-year survival rate of just 6.9%.
Trotman was referred to the Neurology and Neurosurgery Hospital at London Hospital, University of London (UCLH) and treated by consultant Dr. Paul Malholland, Ph.D., UCLH Medical Oncology Dr., as detailed in the press release.
The ancient “Pharaoh Curse” fungus is promising to kill cancer cells
The only person enrolled in a trial that was eventually closed due to a patient shortage, Trotman received a drug called ipilimumab, a targeted immunotherapy treatment.
Ipilimumab is an antibody that binds to proteins in immune cells (T cells) and maintains it. Cancer cells According to the National Cancer Institute, it suppresses the immune system so that it can attack and kill cancer.
Ben Trotman, depicted as his wife, Emily and daughter Mabel, was 40 years old when he was diagnosed with glioblastoma, the most aggressive cancerous brain tumor in 2022. (Marymangan via University College London)
Trotman also received radiation and chemotherapy. More than two years later, his quarterly scans show no signs of cancer.
“It’s very rare to have a clear scan with glioblastoma, especially if he hasn’t had a follow-up procedure that will remove all the tumors he’s first seen on the scan,” his oncologist, Mulholland, said in the release.
“We felt we had a lucky break in an otherwise devastating situation.”
“Immunotherapy and Follow-up treatment Ben kept his tumor at bay — and so far, we are pleased to see. ”
Two months after receiving ipilimumab, Trotman married his wife, Emily. In April 2025, they welcomed their daughter Mabel.
Two months after receiving ipilimumab, Trotman married his wife, Emily. In April 2025, they welcomed their daughter Mabel. (Ben and Emily Trotman via University College London)
“Getting this diagnosis was the most traumatic experience. We were working on the fact that Ben was clearly in perfect health and that he ended up living for several months,” Emily Trotman said in the release.
Click here to get the Fox News app
“If we hadn’t seen Dr. Mulholland, it would have been for us. We felt we had a lucky break in an otherwise devastating situation.”
Ben Trotman added: Immunotherapy Treatment And getting these encouragement scan results gave us a bit of hope. ”
Dr. Paul Mulholland (left) is portrayed in Dame Siobhain McDonagh (right), who raised funds to support new trials of experimental glioblastoma drugs. (Marymangan via University College London)
“We focus on reconstructing the lives we thought we had lost and enjoying being parents.”
Mulholland and his team have now opened another team Clinical trials For patients newly diagnosed with glioblastoma.
Click here to sign up for our health newsletter
Sixteen patients will be recruited for the UCL-sponsored trial. According to the press release, treatment will be administered at NIHR UCLH’s clinical research facility and at the National Hospital of Neurosurgery.
Patients receive ipilimumab before proceeding to standard care Surgery may be includedradiation therapy and chemotherapy.
Glioblastoma patients typically live on an average of 15 months after diagnosis, with a 5-year survival rate of just 6.9%. (istock)
“A key element of this trial is that patients have their own Immune system When they were sufficient to fit and endure immunotherapy, they were increased by medication before they were given other treatments,” Mulholland said in the release.
The Win-Glio trial, dubbed the “Margaret Trial,” is funded by the efforts of Dame Siobhain McDonagh, a sister to Margaret McDonagh, a London woman who died of glioblastoma in 2023 and was treated by Mulholland.
Visit us for more health articles www.foxnews.com/health
Ben said he was “pleased” that the new trials are moving forward with the same immunotherapeutic drugs he took.
“It would give some hope to those newly diagnosed with glioblastoma.”